Project Grant R01HL179440
Award Date 9/1/25
Completion Date 6/30/29
Dollars Obligated $504K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $765,622 to Yale University, with a sub-award to the Children's Hospital of Philadelphia, to develop orally bioavailable protein degraders targeting fetal hemoglobin gene repressors. The goal is to elevate fetal hemoglobin levels and prevent erythroid sickling to treat sickle cell disease. The award period runs from January 1, 2025 to November 30, 2028....
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...
- This federal Project Grant award for $111,626.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage populations and their role in pulmonary hypertension associated with sickle cell disease. The 2-year research project aims to determine if targeting iron release can modify CD169+ macrophages and adaptive immune cells, and if ablation of CD169+ macrophages can inhibit the progression of...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $646,383 to Emory University to evaluate the impact of donor and recipient factors on the survival of transfused red blood cells (RBCs) in recipients with sickle cell disease. The research aims to examine mechanisms contributing to RBC clearance in both the recipient and the donor, including the impact of RBC...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $168,048 to Yale University to conduct research on investigating platelet immune mechanisms in sickle cell disease. The primary goals are to 1) characterize heterogeneous platelet subpopulations and their contribution to vaso-occlusive disease in sickle cell patients, and 2) investigate specific immunothrombotic pathways and mechanisms of platelet activation...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- This $755,853.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to target the pathophysiology of sickle cell-related kidney disease using SGLT2 inhibitors. The key products and services to be delivered through this funding include: Evaluating whether the SGLT2 inhibitor empagliflozin improves biomarkers of kidney function and injury, as well as measures of kidney perfusion, oxygenation, and fibrosis using functional...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The research aims to: 1) define the relationship between SCD adverse outcomes and single-cell biochemical/mechanical properties to identify the most promising biomarkers; 2) define the...